Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw unusually-high trading volume on Thursday . Approximately 1,355,095 shares changed hands during trading, an increase of 192% from the previous session’s volume of 464,733 shares.The stock last traded at $3.5360 and had previously closed at $3.53.

Wall Street Analyst Weigh In

IVA has been the topic of several research reports. Truist Financial began coverage on shares of Inventiva in a report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target on the stock. Wall Street Zen lowered shares of Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Inventiva presently has an average rating of “Buy” and an average target price of $16.56.

Inventiva Price Performance

The company has a 50-day moving average price of $4.88 and a two-hundred day moving average price of $5.36.

Inventiva (NASDAQ:IVA) last announced its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The company had revenue of $0.01 million during the quarter. As a group, research analysts expect that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current fiscal year.

Institutional Trading of Inventiva

Hedge funds have recently made changes to their positions in the company. Creative Planning purchased a new position in shares of Inventiva in the second quarter valued at $32,000. Commonwealth Equity Services LLC grew its holdings in Inventiva by 19.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after purchasing an additional 12,704 shares in the last quarter. Virtu Financial LLC purchased a new stake in Inventiva during the 4th quarter worth $60,000. XTX Topco Ltd acquired a new position in Inventiva in the 4th quarter worth $84,000. Finally, NewEdge Advisors LLC acquired a new position in Inventiva in the 3rd quarter worth $116,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.